SCHEMBL2023488

SCHEMBL2023488

CCCOC(=O)NC1Cc2c(n(Cc3cccc(F)n3)c3ccc(C#N)cc23)C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCARB1 Q8WTV0 2/20 0.34
▸ CHRM4 P08173 1/20 0.34
▸ HRH1 P35367 2/20 0.33
▸ HTR6 P50406 2/20 0.33
▸ CNR1 P21554 2/20 0.32
▸ PTGDR2 Q9Y5Y4 1/20 0.32
▸ RORC P51449 2/20 0.32
▸ DRD2 P14416 2/20 0.31
▸ CACNA1F O60840 1/20 0.31
▸ HTR1A P08908 1/20 0.31
▸ ADORA3 P0DMS8 1/20 0.31
▸ DRD1 P21728 1/20 0.31
▸ DRD4 P21917 1/20 0.31
▸ DRD5 P21918 1/20 0.31
▸ SLC6A2 P23975 1/20 0.31
▸ HRH2 P25021 1/20 0.31
▸ ADRA1D P25100 1/20 0.31
▸ HTR1B P28222 1/20 0.31
▸ HTR2A P28223 1/20 0.31
▸ HTR2C P28335 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12579037 1.00 SCARB1 (0.34) SCARB1CHRM4HRH1HTR6CNR1
SCHEMBL2024659 0.94 SCARB1 (0.34) SCARB1CHRM4HRH1HTR6PTGDR2
SCHEMBL12579036 0.94 SCARB1 (0.34) SCARB1CHRM4HRH1HTR6PTGDR2
SCHEMBL12579040 0.91 SCARB1 (0.36) SCARB1HRH1HTR6PTGDR2DRD2
SCHEMBL2025883 0.91 SCARB1 (0.36) SCARB1HRH1HTR6PTGDR2DRD2
SCHEMBL12579044 0.90 PTGDR2 (0.33) SCARB1CHRM4HRH1HTR6CNR1
SCHEMBL2026354 0.90 PTGDR2 (0.33) SCARB1CHRM4HRH1HTR6CNR1
SCHEMBL2025967 0.90 PTGDR2 (0.33) SCARB1CHRM4HRH1HTR6CNR1
SCHEMBL2025356 0.90 PTGDR2 (0.33) SCARB1CHRM4HRH1HTR6CNR1
SCHEMBL12579034 0.88 HRH1 (0.34) SCARB1HRH1HTR6CNR1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2094658-B1 TETRAHYDROCYCLOPENTA[B]INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS LILLY CO ELI (US) 2011-12-21 — — EP disclosed
US-7968587-B2 Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-06-28 — — US disclosed
US-20100069404-A1 TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS ELI LILLY AND COMPANY 2010-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069404-A1 TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, NR5A1, MUSK SCARB1 1045/4885CHRM4 490/4885HRH1 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback